Orphagen Pharmaceuticals Inc.
This article was originally published in Start Up
Orphagen Pharmaceuticals makes screening for orphan nucelar receptors, which have a notoriously low hit-rate and high rate of false positives, more efficient. It is currently screening for cholesterol-lowering drugs; an oral drug to suppress male hormones, for treating early-stage metastatic prostate cancer; and compounds to modulate the immune system, to treat HIV/AIDS and inflammatory or auto-immune diseases.
You may also be interested in...
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.